Medexus Pharmaceuticals Inc MDP.NE
CAD5.06 CAD0.01 (0.20%) 1D
Last Updated: Sep 04, 12:00 AM·NEO
Pricing for CA stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Medexus Pharmaceuticals Inc Stock Halal?
Shariah Compliance Analysis of MDP.NE Stock
Canada Health Care Micro Cap No. As of September 2026, Medexus Pharmaceuticals Inc (MDP.NE) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Medexus Pharmaceuticals Inc does not pass Musaffa's business and financial screening criteria.
Medexus Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products and treatment solutions focusing on therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. The company is headquartered in Toronto, Ontario and currently employs 91 full-time employees. The company went IPO on 2012-03-03. The firm has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. The company operates through two product portfolios: Medexus Pharma Canada and Medexus Pharma. Its lead products are IXINITY (US), GRAFAPEX (US), Trecondyv (Canada), Rupall (Canada), Rasuvo (US), Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
MDP.NE Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Medexus Pharmaceuticals Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Medexus Pharmaceuticals Inc (MDP.NE) Chart
Financial Metrics & Statements of Medexus Pharmaceuticals Inc (MDP.NE)
FAQ's for Medexus Pharmaceuticals Inc (MDP.NE)
- As of September 2026, Medexus Pharmaceuticals Inc MDP.NE is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Medexus Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Medexus Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Medexus Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Medexus Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Medexus Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Medexus Pharmaceuticals Inc (MDP.NE)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
